leisure time -WSS

leisure time

author：Wikipedia 2025-10-03 00:39:24 - browse：5674

Rachel Haurwitz of Caribou Biosciences — Rachel Haurwitz, CEO of Caribou Biosciences. Elizabeth D. Herman for STAT

Caribou Biosciences said Thursday that its off-the-shelf CAR-T therapy induced durable, complete remissions in patients with advanced B-cell lymphoma that move it closer to the benchmarks set by more established, patient-specific CAR-T therapies.

In an update to an early-stage study, 44% of the 16 patients treated with Caribou’s on-demand therapy, called CB-010, achieved a complete remission lasting a minimum of six months — a key threshold of durability.

The CB-010 result is still preliminary, but it begins to compare favorably to currently approved CAR-T therapies, which must be custom made for each patient and have shown durable remission rates in the range of 36-40%, said Caribou CEO Rachel Haurwitz.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

hotspot

WSS

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Teladoc has a new CEO, but challenges remain the same

Lilly's Alzheimer's drug donanemab backed by FDA advisers

PhRMA lawsuit over Medicare drug price negotiation tossed

How digital tools helped lower hypertension in marginalized patients

hotspot

leisure time

focus

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Biogen Alzheimer’s drug launch off to slow start

As demand for Covid shots wanes, Moderna seeks its next success

Deposition: Sackler embraced plan to conceal OxyContin’s strength

What does generative AI mean for health care? We asked experts

5 takeaways from STAT's examination of Zynex Medical

ChatGPT in medicine: STAT answers readers' burning questions

ALS patient reclaims some autonomy thanks to wearable 'robot'

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Medical mystery: When a cough is not just a cough

explore

Biden report: The neurospychology of memory and aging

Why did Pfizer dish out millions for a Super Bowl ad?

5 takeaways from STAT's examination of Zynex Medical

To avoid data mishandling cases, universities eye AI and other tools

Medicare Advantage proposed rates disappoint insurers

Why did Pfizer dish out millions for a Super Bowl ad?

entertainment

focus

hotspot

knowledge